MARKET

REPL

REPL

Replimune Group
NASDAQ
13.42
+0.55
+4.23%
Opening 15:38 09/22 EDT
OPEN
12.93
PREV CLOSE
12.87
HIGH
13.62
LOW
12.80
VOLUME
901.21K
TURNOVER
--
52 WEEK HIGH
16.33
52 WEEK LOW
1.500
MARKET CAP
1.26B
P/E (TTM)
-4.2458
1D
5D
1M
3M
1Y
5Y
1D
How More Authorized Shares Will Impact Replimune Group (REPL) Stock Investors
Simply Wall St · 7h ago
Weekly Report: what happened at REPL last week (0914-0918)?
Weekly Report · 1d ago
Replimune shareholders approve stock expansion and governance items
TipRanks · 5d ago
Replimune Says Stockholders Approved Amendment To Increase Authorized Common Shares From 150M To 300M, Effective September 15
Benzinga · 5d ago
Trump Administration Shift Puts This Corner of Biotech Back in Favor - Heard on the Street
The Wall Street Journal · 6d ago
Is Replimune Group (REPL) Fully Valued Following Its RP1 Class Action News?
Simply Wall St · 6d ago
HQL: The Rally That Makes Growth Harder (Rating Downgrade)
Seeking Alpha · 09/15 10:30
Weekly Report: what happened at REPL last week (0907-0911)?
Weekly Report · 09/14 09:09
More
About REPL
Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the development of novel oncolytic immunotherapies. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. It has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.

Webull offers Replimune Group Inc stock information, including NASDAQ: REPL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, REPL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading REPL stock methods without spending real money on the virtual paper trading platform.